Home » Acuity Says Primate Data on RNAi Drug Positive, Schedules Meeting with FDA

Acuity Says Primate Data on RNAi Drug Positive, Schedules Meeting with FDA

Nov 14, 2003
Premium

Acuity Pharmaceuticals said this week that data from a recently completed primate study of Cand5, its RNAi treatment for age-related macular degeneration, indicate that the drug is both safe and effective.

The company has also scheduled a meeting with US regulators to discuss the details of filing an investigational new drug application for Cand5, RNAi News has learned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

A Winning Diagnostic

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

Science in Africa Unevenly Funded

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

Not Enough Progress?

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

This Week in Science

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Dec
03
Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Featured Webinar

Clinical-Grade Exome Analysis for Complex and Unsolved Case Investigations

Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.